Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aggressive multiple sclerosis-is there a role for stem cell transplantation?

Eva Havrdova1

  • 1Department of Neurology, First School of Medicine, Charles University, Katerinska 30, 12808 Praha 2, Czech Republic. ehavr@LF1.cuni.cz

Journal of Neurology
|September 20, 2005
PubMed
Summary

Hematopoietic stem cell transplant (HSCT) offers a promising aggressive therapy for malignant multiple sclerosis (MS) when conventional drugs fail. This approach shows significant benefit for over 60% of patients, though transplant risks require further reduction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum bilirubin concentrations and their association with clinical and radiological outcomes in multiple sclerosis: A large cohort study.

Annals of hepatology·2025
Same author

Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.

Journal of neurology, neurosurgery, and psychiatry·2022
Same author

Assessment of T2 lesion-based disease activity volume outcomes in predicting disease progression in multiple sclerosis over 10 years.

Multiple sclerosis and related disorders·2022
Same author

Time course of lesion-induced atrophy in multiple sclerosis.

Journal of neurology·2022
Same author

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.

PharmacoEconomics·2021
Same author

Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis.

Neurology·2021

Area of Science:

  • Neuroimmunology
  • Hematology
  • Transplantation Medicine

Background:

  • Malignant multiple sclerosis (MS) presents a therapeutic challenge unresponsive to conventional disease-modifying drugs, cytostatic regimens, and steroids.
  • A subset of MS patients exhibits aggressive disease activity that necessitates exploring advanced treatment modalities.

Purpose of the Study:

  • To evaluate the efficacy and feasibility of high-dose immunosuppression followed by hematopoietic stem cell transplant (HSCT) for patients with malignant MS.
  • To assess the potential of HSCT in stabilizing or improving disease course in refractory MS cases.

Main Methods:

  • A clinical trial involving 85 patients with malignant MS who had exhausted conventional treatment options.
  • Administration of high-dose immunoablation followed by autologous or allogeneic hematopoietic stem cell transplantation.

Related Experiment Videos

Main Results:

  • Over 60% of patients treated with HSCT demonstrated significant benefit, indicating disease stabilization or improvement.
  • HSCT was found to be a justified and feasible treatment option for this specific patient cohort.

Conclusions:

  • Hematopoietic stem cell transplant (HSCT) represents a viable and effective therapeutic strategy for select patients with malignant multiple sclerosis.
  • Further research is warranted to mitigate transplant-related mortality and optimize HSCT protocols for autoimmune diseases like MS.